University of Oklahoma launches open-rank faculty search for a new oncology science department
The University of Oklahoma Health Sciences Center is building out a newly established Department of Oncology Science and is recruiting assistant, associate, and full professors to join the College of Medicine. The search is open across career stages, a signal that the department is trying to assemble both immediate research capacity and long-term academic depth at the same time. Faculty hires will also be affiliated with the NCI-designated OU Health Stephenson Cancer Center, giving the new department a direct link to an established cancer center infrastructure.
This is more than a standard faculty opening. A newly formed department in oncology science usually reflects a strategic bet on cancer research as a growth area for the institution, especially when the hiring brief is built around mechanistic and translational expertise rather than a single disease site. The areas named in the search—cancer metabolism, cancer signaling, epigenetics, tumor immunology, and chemical biology—sit at the core of contemporary cancer biology, where drug development, biomarker discovery, and pathway analysis increasingly intersect.
Research priorities center on cancer biology and cross-disciplinary science
The faculty call is aimed at investigators who can advance cancer science through fundamental and translational research. Candidates working in metabolism, signaling, epigenetics, tumor immunology, and chemical biology are specifically encouraged to apply, and the department also seeks scientists whose programs connect cancer biology with diabetes, aging, and neurosciences. That broader framing suggests an interest in biology that reaches beyond isolated tumor pathways and into systemic disease mechanisms that shape cancer initiation, treatment response, and survivorship.
The list of priorities maps closely onto some of the most consequential questions in oncology today. Metabolic rewiring supports tumor growth and therapy resistance. Signaling networks drive proliferation and survival. Epigenetic regulation alters gene expression without changing the genome itself, often creating reversible vulnerabilities that drug developers are trying to exploit. Tumor immunology remains central to checkpoint blockade, cellular therapies, and resistance biology. Chemical biology, meanwhile, often supplies the molecular tools needed to probe those systems and translate them into therapeutic concepts.
One sentence in the recruitment brief stands out for its breadth: investigators with cancer biology programs that interface with diabetes, aging, and neurosciences are also welcome. That kind of cross-talk matters because cancer does not evolve in isolation from host biology. Metabolic disease can affect cancer risk and treatment tolerance. Aging shapes the immune microenvironment and treatment resilience. Neurological pathways may influence symptom burden, survivorship, or the biology of tumors that intersect with the nervous system.
Start-up support and independent research space are part of the package
Selected faculty will receive competitive salaries and start-up support for a period of 5 years. Salary will be commensurate with experience, and the amount of start-up funding will depend on committee review of the proposed research and goals. For an academic cancer hire, that support can determine whether a laboratory launches quickly enough to compete for grants, recruit trainees, and generate the first data set needed for external funding.
The emphasis on independent research programs is explicit. Applicants must be able to manage an autonomous scientific agenda and bring a strong publication record in cancer to the table, ideally in high-impact journals. Investigators with NCI funding are especially encouraged to apply, indicating that the department is looking for researchers with a track record of sustained peer-reviewed support and scientific productivity. In practical terms, the search is aimed at people who can contribute to grant success, institutional visibility, and collaborative science from the outset.
A five-year start-up horizon can be particularly attractive in fields where the experimental runway is long. Cancer metabolism and tumor immunology often require complex platforms, specialized reagents, and careful validation before projects yield publishable or fundable outcomes. Extended support gives new faculty time to build data-generating systems rather than chasing immediate outputs at the expense of scientific quality.
A department built for collaboration rather than siloed hiring
The newly established department will sit within a larger academic and cancer center framework, and that structure is important. Faculty members will be affiliated with the Stephenson Cancer Center, creating a channel for interdisciplinary collaboration across basic science, translational studies, and clinical oncology. In cancer research, proximity to a designated cancer center can shape everything from shared core access to clinical sample availability and trainee recruitment.
The job posting also reflects a strong preference for applicants who can contribute to a broader academic mission. Alongside the research plan, candidates must submit a teaching statement and provide professional references. That signals that the department is not recruiting only as a laboratory unit; it is building a full faculty cohort with educational, mentoring, and service responsibilities. For medical scientists, those obligations often determine whether a department becomes a durable training environment or simply a collection of individual labs.
Applications will be reviewed immediately and accepted until the positions are filled, with appointments set to begin as early as 2027. The open timeline suggests the institution is willing to remain flexible on timing while it identifies the right mix of seniority, funding profile, and scientific direction.
A new department can change the pace of an institution’s cancer science only if the hires are strategically chosen. Here, the search parameters point to investigators who can connect molecular mechanism to translational relevance and who can build programs substantial enough to anchor a department from its first years.
What the search reveals about institutional priorities
The hiring profile offers a clear read on where the University of Oklahoma Health Sciences Center wants to invest. It is prioritizing scientists who can work at the interface of fundamental biology and cancer relevance, especially in areas where pathways, metabolism, and immune regulation may drive therapeutic innovation. The inclusion of epigenetics and chemical biology suggests an appetite for discovery science; the inclusion of tumor immunology and cancer signaling suggests translational momentum.
Applicants are being asked to send a curriculum vitae, a three-page research plan covering three to five years, a teaching statement, and three to five references with contact information. Those requirements are standard for faculty recruitment, but they also reveal what the committee is likely to value: a coherent research trajectory, evidence of educational commitment, and external confirmation of scientific independence.
The posting does not spell out a clinical program, patient-facing service line, or disease-specific mandate. Its focus remains squarely on oncology science as a research enterprise, with the expectation that successful hires will deepen the intellectual and experimental base of the new department. In a field where tumor biology changes rapidly and competitive funding is tight, the real test will be whether the department can attract investigators whose science is strong enough to shape the next phase of cancer research at the institution.